Literature DB >> 25209551

Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?

Frank Lohr1, Dietmar Georg, Luca Cozzi, Hans Theodor Eich, Damien C Weber, Julia Koeck, Barbara Knäusl, Karin Dieckmann, Yasser Abo-Madyan, Christian Fiandra, Rolf-Peter Mueller, Andreas Engert, Umberto Ricardi.   

Abstract

PURPOSE: Hodgkin lymphoma (HL) is a highly curable disease. Reducing late complications and second malignancies has become increasingly important. Radiotherapy target paradigms are currently changing and radiotherapy techniques are evolving rapidly.
DESIGN: This overview reports to what extent target volume reduction in involved-node (IN) and advanced radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT) and proton therapy-compared with involved-field (IF) and 3D radiotherapy (3D-RT)- can reduce high doses to organs at risk (OAR) and examines the issues that still remain open.
RESULTS: Although no comparison of all available techniques on identical patient datasets exists, clear patterns emerge. Advanced dose-calculation algorithms (e.g., convolution-superposition/Monte Carlo) should be used in mediastinal HL. INRT consistently reduces treated volumes when compared with IFRT with the exact amount depending on the INRT definition. The number of patients that might significantly benefit from highly conformal techniques such as IMRT over 3D-RT regarding high-dose exposure to organs at risk (OAR) is smaller with INRT. The impact of larger volumes treated with low doses in advanced techniques is unclear. The type of IMRT used (static/rotational) is of minor importance. All advanced photon techniques result in similar potential benefits and disadvantages, therefore only the degree-of-modulation should be chosen based on individual treatment goals. Treatment in deep inspiration breath hold is being evaluated. Protons theoretically provide both excellent high-dose conformality and reduced integral dose.
CONCLUSION: Further reduction of treated volumes most effectively reduces OAR dose, most likely without disadvantages if the excellent control rates achieved currently are maintained. For both IFRT and INRT, the benefits of advanced radiotherapy techniques depend on the individual patient/target geometry. Their use should therefore be decided case by case with comparative treatment planning.

Entities:  

Mesh:

Year:  2014        PMID: 25209551     DOI: 10.1007/s00066-014-0719-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  59 in total

1.  Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.

Authors:  Julia Koeck; Yasser Abo-Madyan; Frank Lohr; Florian Stieler; Jan Kriz; Rolf-Peter Mueller; Frederik Wenz; Hans Theodor Eich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

2.  Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality.

Authors:  Frank Lohr; Mostafa El-Haddad; Barbara Dobler; Roland Grau; Hans-Joerg Wertz; Uta Kraus-Tiefenbacher; Volker Steil; Yasser Abo Madyan; Frederik Wenz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-28       Impact factor: 7.038

3.  Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.

Authors:  Bradford S Hoppe; Stella Flampouri; Zhong Su; Christopher G Morris; Naeem Latif; Nam H Dang; James Lynch; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-10-17       Impact factor: 7.038

4.  Second cancers following pediatric Hodgkin's disease.

Authors:  S L Wolden; K R Lamborn; S F Cleary; D J Tate; S S Donaldson
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study.

Authors:  C Lütgendorf-Caucig; I Fotina; E Gallop-Evans; L Claude; J Lindh; T Pelz; B Knäusl; D Georg; R Pötter; K Dieckmann
Journal:  Strahlenther Onkol       Date:  2012-10-10       Impact factor: 3.621

6.  Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.

Authors:  Damien C Weber; Safora Johanson; Nicolas Peguret; Luca Cozzi; Dag R Olsen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

7.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

8.  Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.

Authors:  Bhishamjit S Chera; Christina Rodriguez; Christopher G Morris; Debbie Louis; Daniel Yeung; Zuofeng Li; Nancy P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-20       Impact factor: 7.038

Review 9.  Range uncertainties in proton therapy and the role of Monte Carlo simulations.

Authors:  Harald Paganetti
Journal:  Phys Med Biol       Date:  2012-05-09       Impact factor: 3.609

10.  Protection of quality and innovation in radiation oncology: the prospective multicenter trial the German Society of Radiation Oncology (DEGRO-QUIRO study). Evaluation of time, attendance of medical staff, and resources during radiotherapy with IMRT.

Authors:  H Vorwerk; K Zink; R Schiller; V Budach; D Böhmer; S Kampfer; W Popp; H Sack; R Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2014-03-05       Impact factor: 3.621

View more
  9 in total

1.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

Review 2.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

Review 3.  Radiation-induced camptocormia and dropped head syndrome: Review and case report of radiation-induced movement disorders.

Authors:  Clemens Seidel; Thomas Kuhnt; Rolf-Dieter Kortmann; Kathrin Hering
Journal:  Strahlenther Onkol       Date:  2015-06-14       Impact factor: 3.621

4.  Quality control of involved field radiotherapy in the HD 13 and HD 14 trials : Report of the radiotherapy panel of the German Hodgkin Study Group (GHSG).

Authors:  J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfart; P Lukas; A Plütschow; H Schmidberger; S Staar; M Fuchs; A Engert; H T Eich
Journal:  Strahlenther Onkol       Date:  2016-09-05       Impact factor: 3.621

5.  Patterns of failure of diffuse large B‑cell lymphoma patients after involved-site radiotherapy.

Authors:  Eva Holzhäuser; Maximilian Berlin; Daniel Wollschläger; Thomas Bezold; Arnulf Mayer; Georg Heß; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2017-07-26       Impact factor: 3.621

6.  Flat detector cone-beam CT-guided percutaneous needle biopsy of mediastinal lesions: preliminary experience.

Authors:  Dechao Jiao; Kai Huang; Gang Wu; Yanli Wang; Xinwei Han
Journal:  Radiol Med       Date:  2016-06-22       Impact factor: 3.469

7.  Heart-sparing volumetric modulated arc therapy for whole lung irradiation.

Authors:  Alexandros Papachristofilou; Anna-Lena Hottinger; Oliver Weinhold; Yasar-Kemal Avcu; Tobias Finazzi; Tamara Diesch; Ulrich Schratzenstaller
Journal:  Strahlenther Onkol       Date:  2018-09-06       Impact factor: 3.621

8.  The impact of protocol assignment for older adolescents with hodgkin lymphoma.

Authors:  Richard S Pieters; Henry Wagner; Stephen Baker; Karen Morano; Kenneth Ulin; Maria Giulia Cicchetti; Maryann Bishop-Jodoin; Thomas J FitzGerald
Journal:  Front Oncol       Date:  2014-11-28       Impact factor: 6.244

9.  Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY.

Authors:  Christian Baues; Simone Marnitz; Andreas Engert; Wolfgang Baus; Karolina Jablonska; Antonella Fogliata; Andrés Vásquez-Torres; Marta Scorsetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2018-07-03       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.